
Precipio PRPO
$ 32.37
8.99%
Annual report 2025
added 03-30-2026
Country |
|
IPO year |
- |
Industry |
Diagnostics research |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
1.61 M |
Market Cap[1] |
$ 52 M |
EBITDA (LTM) |
$ -7.34 M |
P/E (LTM) |
-32.05 |
P/S (LTM) |
2.3 |
EPS (LTM) |
-1.01 |
Other stocks of industry "Diagnostics research"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | Nasdaq Global Market | ||
|
Agilent Technologies
A
|
$ 117.53 | 4.77 % | $ 35.7 B | NYSE,SPB | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | Nasdaq Capital Market | ||
|
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | Nasdaq Capital Market,SPB | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | Nasdaq Global Select Market | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | Nasdaq Capital Market | ||
|
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | Nasdaq Global Select Market | ||
|
CareDx, Inc
CDNA
|
$ 20.7 | -1.24 % | $ 1.1 B | Nasdaq Global Market,SPB | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | Nasdaq Capital Market | ||
|
Check-Cap Ltd.
CHEK
|
- | - | $ 9.42 M | Nasdaq Capital Market | ||
|
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | Nasdaq Capital Market | ||
|
Co-Diagnostics
CODX
|
$ 1.59 | 1.27 % | $ 2.12 M | Nasdaq Capital Market | ||
|
Castle Biosciences
CSTL
|
$ 24.6 | -3.61 % | $ 683 M | Nasdaq Global Market,SPB | ||
|
Koninklijke Philips N.V.
PHG
|
$ 26.45 | 0.8 % | $ 20 B | NYSE | ||
|
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | NYSE | ||
|
Fluidigm Corporation
FLDM
|
- | 1.08 % | $ 308 M | Nasdaq Global Select Market | ||
|
Genetic Technologies Limited
GENE
|
- | - | $ 7.1 B | Nasdaq Capital Market | ||
|
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | Nasdaq Global Market | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | Nasdaq Capital Market,SPB | ||
|
Charles River Laboratories International
CRL
|
$ 185.39 | 7.58 % | $ 9.19 B | NYSE,SPB | ||
|
PRA Health Sciences, Inc.
PRAH
|
- | - | $ 10.7 B | Nasdaq Global Select Market | ||
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | NYSE | ||
|
Exact Sciences Corporation
EXAS
|
- | - | $ 19.8 B | Nasdaq Capital Market,SPB | ||
|
Fulgent Genetics
FLGT
|
$ 14.9 | -1.46 % | $ 451 M | Nasdaq Global Market | ||
|
Guardant Health
GH
|
$ 89.52 | -1.81 % | $ 11.2 B | Nasdaq Global Select Market,SPB | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B | Nasdaq Capital Market,SPB | ||
|
ICON Public Limited Company
ICLR
|
$ 121.32 | 8.35 % | $ 10 B | Nasdaq Global Select Market,SPB | ||
|
Illumina
ILMN
|
$ 139.07 | -0.22 % | $ 22.1 B | Nasdaq Global Select Market,SPB | ||
|
Interpace Biosciences
IDXG
|
$ 2.01 | 0.4 % | $ 8.89 M | Nasdaq Global Select Market | ||
|
QIAGEN N.V.
QGEN
|
- | - | $ 10.6 B | NYSE | ||
|
Biomerica
BMRA
|
$ 2.19 | 1.16 % | $ 5.03 M | Nasdaq Capital Market | ||
|
Lantheus Holdings
LNTH
|
$ 85.82 | -2.23 % | $ 5.79 B | Nasdaq Global Select Market,SPB | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 257.14 | 1.64 % | $ 21.4 B | NYSE,SPB | ||
|
Medpace Holdings
MEDP
|
$ 430.32 | 3.19 % | $ 12.4 B | Nasdaq Global Select Market,SPB | ||
|
Celcuity
CELC
|
$ 141.69 | -2.27 % | $ 6.63 B | Nasdaq Global Select Market | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Nasdaq Global Select Market | ||
|
Myriad Genetics
MYGN
|
$ 5.03 | 1.82 % | $ 466 M | Nasdaq Global Select Market,SPB | ||
|
Burning Rock Biotech Limited
BNR
|
$ 17.02 | -0.96 % | $ 180 M | Nasdaq Global Market | ||
|
NeoGenomics
NEO
|
$ 8.86 | -1.56 % | $ 1.13 B | Nasdaq Global Select Market,SPB | ||
|
Neogen Corporation
NEOG
|
$ 9.27 | 1.98 % | $ 2.01 B | Nasdaq Global Select Market,SPB | ||
|
National Research Corporation
NRC
|
$ 18.74 | 2.85 % | $ 419 M | Nasdaq Global Select Market | ||
|
Natera
NTRA
|
$ 206.77 | -2.26 % | $ 20.3 B | Nasdaq Global Select Market,SPB | ||
|
Quest Diagnostics Incorporated
DGX
|
$ 190.84 | -0.34 % | $ 21.2 B | NYSE,SPB | ||
|
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | NYSE,SPB | ||
|
Organovo Holdings
ONVO
|
- | -2.3 % | $ 19.4 M | Nasdaq Capital Market | ||
|
OpGen
OPGN
|
- | -16.95 % | $ 1.54 M | Nasdaq Capital Market | ||
|
PerkinElmer
PKI
|
- | -0.91 % | $ 14.7 B | NYSE,SPB | ||
|
Exagen
XGN
|
$ 3.09 | -0.32 % | $ 66.6 M | Nasdaq Global Market | ||
|
Personalis
PSNL
|
$ 5.56 | -5.76 % | $ 329 M | Nasdaq Global Select Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.